PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 93 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,151,903 | -46.8% | 129,011 | -11.9% | 0.01% | -43.5% |
| Q2 2023 | $4,045,971 | -20.4% | 146,487 | -33.7% | 0.02% | -25.8% |
| Q1 2023 | $5,082,793 | +64.0% | 220,991 | -22.2% | 0.03% | +47.6% |
| Q4 2022 | $3,099,695 | +44.6% | 284,115 | +11.7% | 0.02% | +23.5% |
| Q3 2022 | $2,144,000 | +77.8% | 254,340 | +272.5% | 0.02% | +30.8% |
| Q2 2020 | $1,206,000 | +136.0% | 68,279 | -5.6% | 0.01% | +85.7% |
| Q1 2020 | $511,000 | -21.0% | 72,357 | -21.2% | 0.01% | +16.7% |
| Q4 2019 | $647,000 | +289.8% | 91,831 | +565.0% | 0.01% | +200.0% |
| Q3 2019 | $166,000 | -39.2% | 13,810 | -36.4% | 0.00% | -50.0% |
| Q1 2019 | $273,000 | +42.9% | 21,700 | -23.6% | 0.00% | +33.3% |
| Q4 2018 | $191,000 | -30.0% | 28,400 | +7.2% | 0.00% | -25.0% |
| Q3 2018 | $273,000 | – | 26,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $43,400,000 | 3.81% |
| BVF INC/IL | 3,901,759 | $69,139,000 | 2.70% |
| COMMODORE CAPITAL LP | 498,079 | $8,826,000 | 2.33% |
| Altium Capital Management LP | 346,000 | $6,131,000 | 1.61% |
| Twin Lakes Capital Management, LLC | 139,287 | $2,468,000 | 1.45% |
| Opaleye Management Inc. | 330,222 | $5,852,000 | 1.09% |
| EcoR1 Capital, LLC | 1,443,800 | $25,584,000 | 0.89% |
| OBERMEYER WOOD INVESTMENT COUNSEL, LLLP | 776,689 | $13,763,000 | 0.76% |
| JABODON PT CO | 90,656 | $1,606,000 | 0.66% |
| Artal Group S.A. | 1,500,000 | $26,580,000 | 0.60% |